Additional milestone payment.

No definition available.

Name:	adpt_AdditionalMilestonePayment
Namespace Prefix:	adpt_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Agreement termination amount receivable.

+ References

No definition available.

+ Details

Name:	adpt_AgreementTerminationAmountReceivable
Namespace Prefix:	adpt_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Eligible payments receivable.

+ References

No definition available.

+ Details

Name:	adpt_EligiblePaymentsReceivable
Namespace Prefix:	adpt_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Non-refundable upfront payments received.

+ References

No definition available.

+ Details

Name:	adpt_NonRefundableUpfrontPaymentsReceived
Namespace Prefix:	adpt_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Revenue recognition expected period.

+ References

No definition available.

+ Details

Name:	adpt_RevenueRecognitionExpectedPeriod
Namespace Prefix:	adpt_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Revenue recognition milestone method expected milestone receivable.

+ References

No definition available.

+ Details

Name:	adpt_RevenueRecognitionMilestoneMethodExpectedMilestoneReceivable
Namespace Prefix:	adpt_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Revenue recognized excluding separately negotiated research sequencing contracts.

+ References

No definition available.

+ Details

Name:	adpt_RevenueRecognizedExcludingSeparatelyNegotiatedResearchSequencingContracts
Namespace Prefix:	adpt_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Revenue recognized excluding sequencing revenue.

+ References

No definition available.

+ Details

Name:	adpt_RevenueRecognizedExcludingSequencingRevenue
Namespace Prefix:	adpt_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Term of agreement.

+ References

No definition available.

+ Details

Name:	adpt_TermOfAgreement
Namespace Prefix:	adpt_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045

+ Details

Name:	us-gaap_ContractWithCustomerLiabilityRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_DisaggregationOfRevenueLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130543-203045

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130539-203045

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_TypeOfArrangementAxis=adpt_TranslationalDevelopmentAgreementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=adpt_MRDDevelopmentAgreementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=adpt_GenentechCollaborationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=adpt_RegulatoryMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=adpt_DevelopmentMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=adpt_CommercialMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Revenue - Additional Information (Details) - USD ($)			1 Months Ended	3 Months Ended		6 Months Ended
Revenue - Additional Information (Details) - USD ($)	Jun. 30, 2019	Dec. 18, 2015	Feb. 28, 2019	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Disaggregation Of Revenue [Line Items]
Revenue recognized	$ 4,400,000					$ 19,341,000
Revenue from collaboration agreement				$ 22,138,000	$ 11,568,000	34,804,000	$ 21,283,000
Translational Development Agreements
Disaggregation Of Revenue [Line Items]
Term of agreement		4 years
Agreement termination amount receivable		$ 800,000
Eligible payments receivable		2,300,000
Revenue recognized excluding separately negotiated research sequencing contracts				1,100,000	2,500,000	1,100,000	5,000,000.0
Revenue recognized excluding sequencing revenue				100,000	200,000	200,000	300,000
Translational Development Agreements \| Maximum
Disaggregation Of Revenue [Line Items]
Expected revenue through milestone payments		$ 40,000,000.0
MRD Development Agreements
Disaggregation Of Revenue [Line Items]
Revenue recognized				500,000	$ 600,000	800,000	$ 1,900,000
MRD Development Agreements \| Maximum
Disaggregation Of Revenue [Line Items]
Additional milestone payment receivable	115,000,000.0			115,000,000.0		115,000,000.0
Genentech Collaboration Agreement
Disaggregation Of Revenue [Line Items]
Non-refundable upfront payments received			$ 300,000,000.0			300,000,000.0
Revenue from collaboration agreement				8,500,000		$ 14,800,000
Genentech Collaboration Agreement \| Maximum
Disaggregation Of Revenue [Line Items]
Revenue recognition expected period						8 years
Genentech Collaboration Agreement \| Maximum \| Regulatory Milestones
Disaggregation Of Revenue [Line Items]
Expected revenue through milestone payments	75,000,000.0			75,000,000.0		$ 75,000,000.0
Genentech Collaboration Agreement \| Maximum \| Development Milestones
Disaggregation Of Revenue [Line Items]
Expected revenue through milestone payments	300,000,000.0			300,000,000.0		300,000,000.0
Genentech Collaboration Agreement \| Maximum \| Commercial Milestones
Disaggregation Of Revenue [Line Items]
Expected revenue through milestone payments	1,430,000,000.0			1,430,000,000.0		1,430,000,000.0
Genentech Collaboration Agreement \| Minimum
Disaggregation Of Revenue [Line Items]
Expected revenue through milestone payments	$ 1,800,000			$ 1,800,000		$ 1,800,000
Revenue recognition expected period						7 years